clinical trial · NCT07807995
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Vertex Pharmaceuticals Incorporated·phase3·not yet recruiting·n = 605
Immunoglobulin A NephropathyPovetacicept
brief summary
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
started
Sep 18, 2026
primary completion
Dec 28, 2029
completion
Dec 28, 2029
last updated
Sep 8, 2026
official title
A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol